A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

A First-in-Human (FIH), Multicenter, Open-Label, Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of YH002 in Subjects With Advanced Solid Malignancies

This is an open-label, dose-escalation study of the study drug YH002. The study is designed to determine the safety, tolerability and maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH002 in patients with advanced solid Malignancies

Study Overview

• Status: Completed
• Conditions: Advanced Solid Malignancies
• Intervention / Treatment: Drug: YH002

Detailed Description

This is a single arm clinical trial in subjects with advanced solid tumor receiving multiple doses of YH002 intravenously (IV). YH002 will be administered (IV) in 6-48 patients with advanced solid tumors. An accelerated titration method followed by a traditional 3+3 dose escalation algorithm will be utilized to determine MTD/MAD. Patients will be dosed at Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H every 3 weeks (Q3W).

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 1

Contacts and Locations

Study Locations

• Australia
  • New South Wales
    • Kogarah, New South Wales, Australia, 2217
      • St George Private Hospital
    • Macquarie, New South Wales, Australia, 2162
      • Macquarie University
  • Victoria
    • Frankston, Victoria, Australia, 3199
      • Peninsula & South Eastern Haematology and Oncology Group

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female, aged ≥ 18 years
• Confirmed as histologically or cytologically, locally advanced or metastatic non-resectable solid tumors, must have received and progressed on, or been ineligible for, or intolerant of available standard therapies known to confer clinical benefit or for whom no standard therapy exits
• Subjects enrolled in Dose D, Dose E, Dose F, Dose G, and Dose H cohorts must have at least one measurable lesion per RECIST v1.1
• Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1 and life expectancy no less than 3 months
• Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy except alopecia, < Grade 2 sensory neuropathy, lymphopenia, and endocrinopathies controlled with hormone replacement therapy

Exclusion Criteria:

• Symptomatic central nervous system (CNS) metastases. Subjects with asymptomatic CNS metastases who are radiologically and neurologically stable ≥ 4 weeks following CNS- directed therapy, and do not require corticosteroids or anticonvulsants are eligible for study entry
• Received anticancer therapy or radiation therapy within 5 half-lives or 4 weeks prior to study entry, whichever is shorter
• Received palliative radiotherapy to a single area of metastasis within 2 weeks prior to study entry
• Received agonist antibodies to TNFR such as anti-CD137, OX40, CD27 and CD357 antibodies prior to the study entry
• Allergy or sensitivity to YH002, or known allergies to antibodies produced from Chinese hamster ovary cells which assessed to increase the potential for an adverse hypersensitivity to YH002 by Investigator
• History of a Grade 3-4 allergic reaction to treatment with another monoclonal antibody
• Grade ≥3 irAEs or irAEs that lead to discontinuation of prior immunotherapy. Hypothyroidism, Type 1 DM, and dermatologic irAEs (except previous Steven Johnson Syndrome, toxic epidermal necrolysis, or other severe forms of dermatitis). Type 1 DM should be controlled with reduction of toxicity to Grade 1 or less
• Concomitant active autoimmune disease or history of autoimmune disease requiring systemic treatment or history of autoimmune disease within 2 years prior to study entry (except vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus or hypothyroidism which can be managed by replacement therapy)
• Received steroids or other immunosuppressive systemic therapy within 4 weeks prior to the first dose of the study drug, or has need to be treated during the study (except using on low systemic absorption location prevent or treat non- autoimmune condition)
• Active hepatitis B or C. Hepatitis B carriers without active disease or cured Hepatitis C may be enrolled
• Severe cardiovascular disease within 6 months of study entry

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: YH002; All subject will receive YH002 intravenously as single agent every three weeks (Q3W) for up to 2 years, until intolerable toxicity, confirmed disease progression, withdrawal of consent, or Investigator decision, whichever comes first. Subjects who remain on treatment in the absence of disease progression for more than 2 years may continue to receive study drug through a single patient IND.

Drug: YH002; YH002 will be administered intravenously every three weeks (Q3W) for up to 2 years at doses of Dose A, Dose B, Dose C, Dose D, Dose E, Dose F, Dose G, and Dose H.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	MTD is defined as the highest dose level at which no more than 1 out of 6 subjects experiences a DLT during the first cycle	Cycle 1 of each cohort. Duration of one cycle is 3 weeks
Dose-limiting toxicities (DLT)	DLT is defined as a toxicity (adverse event at least possibly related to YH002) occurring during the DLT observation period (the initial 21 days)	Cycle 1 of each cohort. Duration of one cycle is 3 weeks
Number of participants with adverse events and serious adverse events	The safety profile of YH002 will be assessed by monitoring the adverse events (AE) per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v5.0	From screening up to 2 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the serum concentration versus time curve within one dosing interval (AUCtau)	To determine the pharmacokinetics (PK) profile of YH002	Up to 2 years
Volume of distribution (Vd)	To determine the pharmacokinetics (PK) profile of YH002	Up to 2 years
Volume of distribution at steady state (Vss)	To determine the pharmacokinetics (PK) profile of YH002	Up to 2 years
Maximum serum concentration (Cmax)	To determine the PK profile of YH002 as single agent	Up to 2 years
Trough concentration before the next dose is administered (Ctrough)	To determine the PK profile of YH002	Up to 2 years
Time to reach maximum serum concentration (Tmax)	To determine the PK profile of YH002	Up to 2 years
Clearance (CL)	To determine the PK profile of YH002	Up to 2 years
Terminal half-life (T1/2)	To determine the PK profile of YH002	Up to 2 years
Dose proportionality	To determine the PK profile of YH002	Up to 2 years
Incidence of anti-drug antibodies (ADAs)	To assess the immunogenicity of YH002	Up to 2 years
Incidence of neutralizing antibodies (NAbs)	To assess the immunogenicity of YH002	Up to 2 years
Objective response rate (ORR)	To assess the preliminary antitumor activity of YH002	Up to 2 years
Duration of response (DOR)	To assess the preliminary antitumor activity of YH002	Up to 2 years
Progression free survival (PFS)	To assess the preliminary antitumor activity of YH002	Up to 2 years
Time to response (TTR)	To assess the preliminary antitumor activity of YH002	Up to 2 years
Disease control rate (DCR)	To assess the preliminary antitumor activity of YH002	Up to 2 years
Duration of disease control (DOC)	To assess the preliminary antitumor activity of YH002	Up to 2 years

Collaborators and Investigators

• Sponsor: Eucure (Beijing) Biopharma Co., Ltd

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2020
• Primary Completion (Actual): September 14, 2021
• Study Completion (Actual): November 24, 2021

Study Registration Dates

• First Submitted: April 17, 2020
• First Submitted That Met QC Criteria: April 17, 2020
• First Posted (Actual): April 20, 2020

Study Record Updates

• Last Update Posted (Actual): July 22, 2022
• Last Update Submitted That Met QC Criteria: July 21, 2022
• Last Verified: July 1, 2022

More Information

Terms related to this study

• Keywords: tolerability; safety; pharmacokinetics; dose escalation; advanced solid malignancie
• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: YH002002

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No